Total Tyvaso — Total revenues
United Therapeutics Total Tyvaso — Total revenues decreased by 1.5% to $457.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 1.9%, from $466.30M to $457.50M. Over 4 years (FY 2021 to FY 2025), Total Tyvaso — Total revenues shows an upward trend with a 32.6% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing patient adoption, successful market penetration, or expanded clinical indications, while a decrease may signal increased competition, pricing pressure, or loss of market exclusivity.
Detailed definition
This metric represents the total gross revenue generated from the sale of an inhaled prostacyclin therapy used to treat...
Peer comparison
Comparable to specialized pharmaceutical product revenue lines or orphan drug sales reported by other biotechnology firms focused on rare respiratory or cardiovascular diseases.
uthr_segment_total_tyvaso_total_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $153.80M | $164.20M | $166.50M | $172.00M | $201.00M | $257.70M | $242.30M | $238.40M | $318.90M | $325.80M | $350.60M | $372.50M | $398.20M | $433.80M | $415.90M | $466.30M | $469.60M | $478.00M | $464.30M | $457.50M |
| QoQ Change | — | +6.8% | +1.4% | +3.3% | +16.9% | +28.2% | -6.0% | -1.6% | +33.8% | +2.2% | +7.6% | +6.2% | +6.9% | +8.9% | -4.1% | +12.1% | +0.7% | +1.8% | -2.9% | -1.5% |
| YoY Change | — | — | — | — | +30.7% | +56.9% | +45.5% | +38.6% | +58.7% | +26.4% | +44.7% | +56.3% | +24.9% | +33.1% | +18.6% | +25.2% | +17.9% | +10.2% | +11.6% | -1.9% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is United Therapeutics's total tyvaso — total revenues?
- United Therapeutics (UTHR) reported total tyvaso — total revenues of $457.50M in Q1 2026.
- How has United Therapeutics's total tyvaso — total revenues changed year-over-year?
- United Therapeutics's total tyvaso — total revenues decreased by 1.9% year-over-year, from $466.30M to $457.50M.
- What is the long-term trend for United Therapeutics's total tyvaso — total revenues?
- Over 4 years (2021 to 2025), United Therapeutics's total tyvaso — total revenues has grown at a 32.6% compound annual growth rate (CAGR), from $607.50M to $1.88B.
- What does total tyvaso — total revenues mean?
- The total revenue earned from sales of the company's inhaled pulmonary arterial hypertension medication.